Women and peptide research gaps: trial representation, dose interpretation, and where the gap is closing

Key takeaways

• Until the 1990s, female participants were systematically underrepresented in US phase 1 PK / PD studies. The 1993 NIH Revitalization Act required NIH-funded research to include women and analyze results by sex.
• Modern GLP-1 obesity trials enroll near-balanced sex distributions and report sex-stratified subgroups: STEP-1 was 74 percent female, SURMOUNT-1 was 67 percent. The historical gap has been substantially closed for this drug class.
• Cardiovascular-outcomes GLP-1 trials have lower female enrollment because qualifying-CVD populations skew male: SUSTAIN-6 was 39 percent female, SELECT was 28 percent.
• Older research peptides (BPC-157, TB-500, ipamorelin, CJC-1295) and SARMs (LGD-4033 Basaria 2013, RAD-140) rest on small male-skewed phase 1 cohorts; female-specific PK / PD data are essentially absent.
• GLP-1 agonists are contraindicated in pregnancy; semaglutide labels recommend discontinuation 2 months before planned pregnancy because of long half-life. Lactation safety is similarly limited.

The historical imbalance

Until the 1990s, female participants were systematically underrepresented in many phase 1 pharmacokinetic and pharmacodynamic studies in the United States. Reasons cited at the time included concern about teratogenic exposure (the post-thalidomide regulatory caution), hormonal-cycle variability, and statistical-power considerations on small studies. The downstream effect is that early dose-finding work for many older drug classes was anchored on male physiology.

The 1993 NIH Revitalization Act required NIH-funded clinical research to include women and minorities and to analyze results by sex/gender. Subsequent FDA guidance extended the expectation to drug-development trials. Enrollment of women in trials increased after these mandates , but compliance with sex-stratified analysis and reporting has lagged: an audit of NIH-funded RCTs published in 2015 found only about a quarter reported any outcome by sex, with no significant change from a decade earlier, and coverage remains uneven across drug classes .

What this means for pharmacokinetics

• Body-size differences shift volume of distribution. Per-kilogram dosing helps but does not fully resolve clearance differences for some compounds.
• Body-composition differences (typically higher percent body fat in women) shift volume of distribution for lipophilic drugs.
• Hormonal-cycle effects on hepatic CYP enzymes can shift drug clearance for some classes; CYP3A4 activity in women varies across the menstrual cycle, affecting clearance of substrate drugs.
• Renal clearance differs systematically (lower GFR per body weight in women), shifting half-life of renally cleared drugs.
• Population PK analyses on the modern GLP-1 trials include sex as a covariate; the published label sections summarize what those analyses found .
• Older non-peptide research compounds (some SARMs, older nootropics) have human PK data drawn from much smaller and more male-skewed samples, which is worth knowing when reading dose recommendations.

GLP-1 sex-stratified subgroup data

Modern obesity and diabetes trials of GLP-1 and dual agonists have generally enrolled near-balanced sex distributions and reported sex-stratified subgroup analyses. Headline patterns:

• STEP-1 (semaglutide 2.4 mg): female participants were 74 percent of the cohort; sex-subgroup weight loss was numerically larger in women (-15.7 percent) than men (-12.0 percent), consistent with the broader population pattern of larger relative weight loss in women on GLP-1 therapy .
• SURMOUNT-1 (tirzepatide 5/10/15 mg): 67 percent female; sex-subgroup analysis showed similar relative weight loss across sexes at the higher doses, with somewhat larger response in women at the 5 mg dose .
• SUSTAIN-6 (semaglutide cardiovascular outcomes in T2D): 39 percent female; cardiovascular outcome benefit was directionally similar across sexes but the female subgroup was smaller and CIs were wider .
• SELECT (semaglutide 2.4 mg in established CVD without diabetes): 28 percent female (lower because the qualifying CVD population skews male); cardiovascular outcome benefit was directionally consistent across sexes .

Practical takeaway: GLP-1 efficacy and safety data in women now rest on tens of thousands of female trial participants, including in the long-term outcome trials. The historical gap has been substantially closed for this drug class.

Where the gap is closing, and where it is not

The gap is closing fastest in drug classes with active phase 3 programs (GLP-1, oncology, autoimmune). It remains visible in:

• Older research peptides (BPC-157, TB-500, Ipamorelin, CJC-1295): original PK data from small healthy-male cohorts; female-specific data are essentially absent.
• SARMs: phase 1 cohorts (LGD-4033 Basaria 2013, RAD-140 oncology) heavily male; the limited oncology-population data on RAD-140 is in postmenopausal women but not generalizable.
• Cardiovascular-outcomes peptide trials with low female enrollment because of qualifying-disease sex skew (CVD established disease, HFpEF).
• Pregnancy and lactation safety: postmarketing surveillance is the main lens and accumulates slowly; the FDA pregnancy and lactation labeling rule shapes how this data is presented in product labels .

Menopause and perimenopause considerations

Perimenopausal and postmenopausal women experience metabolic changes (visceral adiposity gain, insulin resistance shifts, lipid changes) that intersect with peptide and GLP-1 therapy in ways that recent trials are starting to characterize. The hormonal-replacement-therapy landscape adds another variable: estrogen status modulates GLP-1 response, lipid handling, and bone metabolism.

Specific subgroup analyses of GLP-1 efficacy in perimenopausal versus postmenopausal versus premenopausal women are sparse in the published literature; most trials report by sex but not by menopausal status. This is a meaningful sub-gap within the broader sex-representation question.

Pregnancy and lactation

GLP-1 agonists and most research peptides are contraindicated or not recommended during pregnancy. Animal reproduction studies have shown adverse effects with semaglutide and tirzepatide; the labels recommend discontinuation 2 months before planned pregnancy for semaglutide and at least 1 month before for tirzepatide because of the long half-life .

Lactation safety data are similarly limited. Most peptide drug labels recommend caution and prescriber consultation. The FDA pregnancy and lactation labeling rule replaced the old A/B/C/D/X categories with descriptive risk summaries; current labels reflect this format .

Future work and live trials

The most useful path forward is sex-stratified subgroup analysis on every adequately powered trial, plus dedicated PK/PD work in female-only cohorts where it has not been done. Pregnancy registries (similar to the existing teratogen registries for other drug classes) for GLP-1 agents and peptide drugs would close meaningful gaps. ClinicalTrials.gov is a reasonable starting point for finding active trials by drug class and population .

Editorial summary

Modern GLP-1 trials have substantially closed the sex-representation gap for this drug class. Older research peptides, SARMs, and any compound whose original PK was characterized pre-1993 still rest on male-skewed samples. Pregnancy and lactation data are limited across the board. Menopausal status is a meaningful sub-question that current trials largely do not stratify on.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.